The ADP-ribosylation factor-like 4A (ARL4A) protein belongs to the ARF/ARL family of small GTPases, which regulate membrane trafficking, cytoskeletal remodeling, and cellular signaling. ARL4A, specifically, plays roles in cell migration, neurite outgrowth, and lipid metabolism by cycling between active GTP-bound and inactive GDP-bound states. It interacts with effectors such as cytohesins and regulates phosphoinositide signaling, impacting cellular processes like vesicle transport and membrane dynamics. Dysregulation of ARL4A has been linked to cancers, neurodevelopmental disorders, and metabolic diseases.
ARL4A antibodies are essential tools for studying its expression, localization, and function. They are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to detect endogenous ARL4A in cell lines, tissues, or experimental models. These antibodies help elucidate ARL4A's involvement in disease pathways or its interaction networks. Most ARL4A antibodies target conserved epitopes, such as the N-terminal region, and are validated for specificity using knockout controls. Available as monoclonal or polyclonal variants, they enable researchers to explore ARL4A's role in development, homeostasis, and pathology, bridging molecular insights to potential therapeutic applications.